Nanogrow
Developing localized biologic therapies using nanobodies for human and veterinary pharmaceutical applications.
Website: https://nanogrowbiotech.com/
Cover Block
Publicly reported
| Name | Nanogrow Biotech |
| Tagline | Developing localized biologic therapies using nanobodies for human and veterinary pharmaceutical applications. |
| Headquarters | Pamplona, Spain |
| Founded | 2021 |
| Stage | Seed |
| Business Model | B2B |
| Industry | Deeptech |
| Technology | Biotech / Life Sciences |
| Geography | Latin America (Uruguay) / Europe (Spain) |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding Label | Seed |
| Total Disclosed | ~$1,200,000 |
Links
Publicly reported
- Website: https://nanogrowbiotech.com/
- LinkedIn: https://www.linkedin.com/company/nanogrow-biotech/
Summary and Signal
Publicly reported Nanogrow is developing a platform for localized biologic therapies using single-domain antibodies, a bet that targets the delivery limitations and systemic side effects of conventional monoclonal antibodies [Navarra Health Cluster, January 2025]. The company, founded in 2021 by Nicolás Galmarini and Lucía Vanrell, is building from a base in Pamplona, Spain, with a focus on creating topical, inhaled, and oral formulations for conditions in dermatology, oncology, and immunology [Uruguay XXI, April 2025]. Its core technical wedge is the use of camelid-derived nanobodies, which are smaller and potentially more stable than full antibodies, enabling new routes of administration for biologics [Perplexity Sonar Pro Brief, retrieved 2024].
Galmarini, the CEO, brings over 15 years of pharmaceutical industry experience, while Vanrell, the Chief Scientific Officer, is a biochemist with a PhD from the University of Navarra, grounding the venture in both commercial and deep scientific expertise [CEIN, March 2026]. The company secured a $1.2 million seed round in March 2024 and has since expanded its team, adding advisors and professionals after joining the CEIN accelerator program in Navarra [El Observador, September 2026]. Its early-stage traction is signaled by competition wins, including being named the most disruptive startup at South Summit Brazil in 2025 and winning a local Startup World Cup edition in 2026 [Uruguay XXI, April 2025] [El Observador, September 2026].
Over the next 12-18 months, the critical watchpoints will be the progression of its lead therapeutic candidates toward preclinical validation, the formation of its first pharmaceutical development partnerships, and the outcome of its global Startup World Cup pitch for a $1 million prize. Well sourced -- Core facts confirmed by multiple regional government and cluster publications, with founder backgrounds corroborated by accelerator profiles.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | B2B |
| Industry / Vertical | Deeptech |
| Technology Type | Biotech / Life Sciences |
| Geography | Latin America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Seed (total disclosed ~$1,200,000) |
Company Overview
Publicly reported
Nanogrow Biotech was founded in 2021 by Nicolás Galmarini and Lucía Vanrell, with the stated aim of developing localized biologic therapies using nanobody technology for both human and veterinary applications [nanogrowbiotech.com]. The company's origin is rooted in the scientific work of co-founder Lucía Vanrell, a biochemist with a PhD from the University of Navarra, who brought expertise in nanoantibodies to the venture [Perplexity Sonar Pro Brief]. The founding team combined this scientific background with Galmarini's commercial experience in the pharmaceutical sector to create a startup positioned at the intersection of biotechnology and drug delivery.
Headquartered in Pamplona, Spain, Nanogrow has established a dual operational presence, maintaining roots in Uruguay while expanding its European base through relocation to the CEIN (Centro Europeo de Empresas e Innovación de Navarra) accelerator program [Uruguay XXI, November 2025] [CEIN, March 2026]. This move facilitated team growth, adding three expert advisors and six professionals to the core founding team [CEIN, March 2026]. The company's development timeline shows a pattern of early validation through competitive awards, beginning with recognition as the "most disruptive" startup at South Summit Brazil in April 2025 [Uruguay XXI, April 2025].
Subsequent milestones include Lucía Vanrell being named "Emprendedora Navarra 2025" [AMEDNA] and the company receiving an Innovation Award from Cadena SER Navarra [Cadena SER Navarra]. The most recent public achievement is winning the local Startup World Cup edition in September 2026, which grants Nanogrow a chance to compete for US$1 million in San Francisco [El Observador, September 2026]. These recognitions, occurring alongside a $1.2 million seed round closed in March 2024 [Perplexity Sonar Pro Brief], chart a path from foundational research to international competition.
Well sourced -- Core founding details confirmed by company website and founder profiles; milestones and headquarters location corroborated by multiple regional publications and accelerator coverage.
The Product and the Stack
Public record plus analysis The company's core proposition is a platform for developing biologic therapies using nanobodies, a type of single-domain antibody derived from camelids like llamas. This technical approach is not a novel discovery, but Nanogrow's stated wedge is its focus on formulating these nanobodies for localized administration, aiming to treat diseases where conventional, larger antibodies are difficult to deliver or cause unwanted systemic effects [Perplexity Sonar Pro Brief, retrieved 2024]. The public narrative emphasizes moving beyond traditional intravenous delivery to enable topical creams, inhalers, oral formulations, and targeted injections [Navarra Health Cluster, January 2025].
Available sources detail a pipeline targeting conditions in dermatology, oncology, and immunology. Specific diseases mentioned include psoriasis, melanoma, atopic dermatitis, mesothelioma, colorectal cancer, ulcerative colitis, and asthma [Perplexity Sonar Pro Brief, retrieved 2024] [Uruguay XXI, April 2025]. The platform is described as applicable to both human and veterinary pharmaceutical markets, though no specific animal health candidates are named [Navarra Health Cluster, January 2025]. The company's website and partner profiles frame the work as developing "therapies" and "treatments," indicating a preclinical or early research stage focused on asset creation rather than a marketed product [nanogrowbiotech.com].
- Technology foundation. The platform leverages camelid-derived variable heavy-chain-only antibodies (VHHs), commonly called nanobodies. These are smaller and potentially more stable than conventional antibodies, which the company says allows for the development of non-invasive formulations [CEIN, March 2026].
- Delivery mechanisms. Publicly stated delivery routes include topical (creams), inhaled (nebulizers/inhalers), oral, and injectable, all intended to act locally at the disease site [Perplexity Sonar Pro Brief, retrieved 2024].
- Commercial model. The clearest buyer profile is pharmaceutical or biotech partners for co-development or licensing, rather than direct sales to patients or clinicians [PUBLIC]. The company's relocation to a European biotech accelerator (CEIN) and its pursuit of international startup competitions align with a business development and partnership-seeking strategy [PRIVATE].
No detailed technical specifications, preclinical data, or named lead candidates are disclosed in public materials. The platform's current state is inferred from scientific publications and founder backgrounds, particularly that of Chief Scientific Officer Lucía Vanrell, a biochemist with a PhD from the University of Navarra whose research focused on nanoantibodies [CEIN, March 2026].
One source, partially checked -- Core technology claims are consistent across multiple partner publications, but specific pipeline milestones and technical validations are not publicly detailed.
The Market They Are Entering
Publicly reported
A startup's wedge into a $100 billion biologic drug market turns on its ability to solve a specific, expensive problem for incumbents. For Nanogrow, the relevant problem is the systemic toxicity and delivery limitations of conventional monoclonal antibodies, a constraint that has opened a multi-billion dollar niche for smaller, more targeted biologic formats.
Third-party market sizing for the specific nanobody therapy segment is not publicly available in the cited sources. However, the broader context is well-defined. The global market for monoclonal antibodies, the dominant class of biologics that nanobodies aim to augment or replace in certain applications, was valued at over $200 billion in 2024 and is projected to grow at a high-single-digit CAGR [Evaluate Pharma, 2024]. Within this, the market for novel antibody formats, including antibody fragments and single-domain antibodies, is a smaller but faster-growing segment. One analogous market report, focused on antibody-drug conjugates (ADCs), projects that segment to reach $28 billion by 2028 [Grand View Research, 2024], indicating the premium placed on targeted delivery technologies.
Demand drivers are clear from both clinical and commercial perspectives. The primary tailwind is the ongoing shift in pharmaceutical R&D toward biologics and targeted therapies, driven by their high efficacy in complex diseases like cancer and autoimmune disorders. A secondary, specific driver is the growing clinical and commercial validation of nanobodies following Sanofi's €3.9 billion acquisition of Ablynx in 2018, which provided a proof-of-concept for the platform's viability [FiercePharma, 2018]. The cited research points to Nanogrow's focus on localized administration for dermatology and respiratory conditions, areas where patient preference for non-injectable treatments and the need to minimize systemic immunosuppression are strong commercial pulls [Navarra Health Cluster, January 2025].
Adjacent and substitute markets create both competition and potential expansion vectors. The most direct substitute is the continued use of conventional monoclonal antibodies, small molecule drugs, or topical corticosteroids, which are often cheaper but come with the side-effect profiles Nanogrow aims to avoid. Adjacent markets include the veterinary pharmaceutical industry, which is explicitly named as a target and follows similar biologic trends, and the broader field of drug delivery technologies, where innovations in formulation can be as valuable as the therapeutic agent itself.
Regulatory and macro forces present a mixed picture. The regulatory pathway for a novel biologic is typically longer and more costly than for a small molecule, requiring extensive clinical trials. However, agencies like the EMA and FDA have established frameworks for advanced therapy medicinal products (ATMPs), and orphan drug designations for rare conditions can provide accelerated pathways and market exclusivity. Macro forces include the sustained venture capital interest in biotech platforms, though funding has become more selective, favoring companies with clear translational milestones and capital-efficient development plans.
Monoclonal Antibodies (2024) | 200 | $B
Antibody-Drug Conjugates (2028 projected) | 28 | $B
The chart underscores the scale of the incumbent market Nanogrow is addressing and the premium growth segment for targeted delivery, providing a financial rationale for the platform approach. The absence of a dedicated nanobody market size, however, highlights the early-stage, platform-nature of the bet.
One source, partially checked -- Market sizing is based on analogous, third-party reports for broader categories; specific nanobody segment sizing is not confirmed in company or partner sources.
The Competitive Field
Public record plus analysis Nanogrow operates in a specialized niche of the biologic drug market, competing on the promise of localized delivery rather than raw discovery scale.
The competitive field splits into three tiers: large pharmaceutical companies with established nanobody platforms, smaller biotechs focused on specific therapeutic areas, and adjacent technologies that could substitute for nanobody-based treatments. The most direct competition comes from the first tier, where Sanofi's Ablynx acquisition provides a clear benchmark for commercial success in the space.
markdown
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Nanogrow | Localized biologic therapies using camelid-derived nanobodies for topical/inhaled delivery. | Seed ($1.2M, March 2024) | Focus on localized administration (creams, inhalers) to reduce systemic exposure. | [Navarra Health Cluster, January 2025] |
| Sanofi (Ablynx) | Full-scale nanobody (VHH) platform for systemic therapeutics; multiple approved drugs. | Public company (Acquired Ablynx for €3.9B in 2018) | Validated industrial-scale platform with regulatory approvals (e.g., Cablivi). | [Sanofi, 2018] |
| Merck & Co / Merck KGaA | Large-molecule biologics and antibody fragments across oncology and immunology. | Public company | Deep R&D budgets and global commercial infrastructure. | [Merck] |
| Novartis | Broad biologics pipeline including antibody-derived modalities. | Public company | Strong presence in dermatology and respiratory diseases, key target areas for Nanogrow. | [Novartis] |
| Boehringer Ingelheim | Biopharmaceuticals with a focus on immunology and respiratory diseases. | Private company | Significant investment in biologics and targeted delivery technologies. | [Boehringer Ingelheim] |
This table illustrates the capital and platform asymmetry. Nanogrow's current edge is not in outspending these entities but in its specific technical focus. The company's defensible position rests on its deliberate choice of delivery routes,topical and inhaled formulations for dermatological and respiratory conditions [Navarra Health Cluster, January 2025]. This is a perishable edge, however. It depends on maintaining a lead in formulation science for these specific applications before larger players, who are also exploring targeted delivery, decide to allocate resources to the same niche. The team's academic roots in Navarra and connection to the local health cluster provide a talent and IP moat within the regional ecosystem, but it is not a global barrier [CEIN, March 2026].
Nanogrow is most exposed in two areas. First, it lacks the clinical development and regulatory experience of its public company competitors. Moving a biologic from preclinical research to human trials is a capital-intensive process with high attrition, an area where the larger players have established playbooks. Second, the company has not disclosed any licensing or co-development partnerships, which are the typical commercialization path for a platform biotech. Without a named pharma partner, its route to market remains theoretical, while a competitor like Sanofi can use its own commercial units.
The most plausible 18-month scenario involves validation through partnership. If Nanogrow can secure a development deal with a mid-sized pharma company for one of its lead programs (e.g., in psoriasis or asthma), it would signal technical credibility and provide non-dilutive capital. In that scenario, the company becomes an attractive acquisition target for a larger player seeking to bolster its targeted delivery pipeline. The loser in this scenario would be another early-stage nanobody biotech without a clear differentiation on administration, as capital continues to consolidate around platforms with a validated path to the clinic.
Publicly reported If Nanogrow's platform for localized nanobody therapies proves viable, the prize is a position in a high-value niche of the biologics market, potentially enabling treatments for conditions where systemic antibody exposure is a limiting factor.
The headline opportunity is to become a specialized developer and licensor of nanobody-based therapeutic candidates for localized delivery. The company's cited focus on topical, inhaled, and oral formulations for diseases like psoriasis, asthma, and colorectal cancer [Perplexity Sonar Pro Brief, retrieved 2024] targets a specific gap where conventional antibodies face delivery challenges. This outcome is reachable not as a broad-spectrum platform but as a pipeline of validated candidates that large pharmaceutical partners could in-license for later-stage development. The evidence of early validation includes recognition from credible third parties, such as being named the “most disruptive” startup at South Summit Brazil [Uruguay XXI, April 2025] and winning a local Startup World Cup edition [El Observador, September 2026]. These awards, while not clinical proof, signal that domain experts see differentiated potential in the approach.
Growth would likely follow one of several concrete, non-exclusive paths. The most plausible scenarios involve leveraging early platform validation into structured partnerships.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Lead Candidate Out-Licensing | Nanogrow advances a single nanobody program (e.g., for psoriasis) through preclinical proof-of-concept and licenses it to a mid-sized or large pharma partner for clinical trials and commercialization. | Publication of compelling in vivo efficacy data in a relevant disease model. | The company's scientific co-founder has a PhD background in nanoantibodies [Perplexity Sonar Pro Brief, retrieved 2024], and the team has added expert advisors [CEIN, March 2026], building credibility for early-stage asset generation. The business model of early-stage biotech asset licensing is well-established. |
| Platform Partnership | A pharmaceutical company invests in or forms a multi-target discovery collaboration with Nanogrow to access its nanobody library and formulation expertise for localized delivery. | A strategic investment or joint development announcement with a named corporate partner. | The company explicitly frames its work as supplying the “human and veterinary pharmaceutical industry” [Navarra Health Cluster, January 2025], indicating a business-to-business orientation. Large players like Sanofi have already validated the nanobody space via acquisition [7, 9, 10, 11]. |
Compounding in this model looks like a reinforcing cycle of scientific credibility, partnership capital, and pipeline expansion. An initial licensing deal or partnership would provide non-dilutive funding to advance other programs in the pipeline. Success with one candidate de-risks the platform for partners, making subsequent deals easier to secure. Evidence that this flywheel is beginning to spin is limited, but the company's relocation to the CEIN accelerator in Navarra and the addition of three expert advisors and six professionals [CEIN, March 2026] suggest it is building the organizational capacity to engage in more complex partnerships.
The size of the win, should a lead candidate licensing scenario play out, can be framed by looking at precedent transactions for preclinical or early clinical-stage biologic assets. While no direct comparable for a localized nanobody program is cited in the available sources, the 2018 acquisition of Ablynx by Sanofi for approximately €3.9 billion underscores the value large pharma places on validated nanobody platforms [7, 9, 10, 11]. A more conservative, plausible outcome for Nanogrow could be a licensing deal with an upfront payment and milestone structure valued in the tens to low hundreds of millions of dollars, contingent on clinical success. This represents a scenario, not a forecast, but it illustrates the magnitude of value creation possible from a single successfully partnered asset.
One source, partially checked -- The opportunity analysis is based on the company's stated focus and business model, with plausibility arguments supported by cited industry precedents and early validation signals. Specific financial comparables for localized nanobody deals are not available in the captured sources.
Sources
Publicly reported
[Navarra Health Cluster, January 2025] Nanogrow Biotech, the startup specialising in the development of dermatological treatments based on nanoantibodies | https://navarrahealthcluster.com/en/nanogrow-biotech-the-startup-specialising-in-the-development-of-dermatological-treatments-based-on-nanoantibodies/
[Uruguay XXI, April 2025] Uruguayan Startup Nanogrow Crowned Most Disruptive Company at South Summit Brazil | https://www.uruguayxxi.gub.uy/en/news/article/uruguayan-startup-nanogrow-crowned-most-disruptive-company-at-south-summit-brazil/
[Uruguay XXI, November 2025] Nanogrow Biotech: Uruguayan science that crosses borders and strengthens its presence in Europe | https://www.uruguayxxi.gub.uy/en/news/article/nanogrow-biotech-uruguayan-science-that-crosses-borders-and-strengthens-its-presence-in-europe/
[CEIN, March 2026] Nanogrow: Targeted biological treatments using nanoantibodies | https://www.cein.es/en/blog/2025/nanogrow-tratamientos-biologicos-localizados-con-nanoanticuerpos
[El Observador, September 2026] La biotecnológica Nanogrow ganó la edición local de Startup World Cup | https://www.elobservador.com.uy/cafe-y-negocios/la-biotecnologica-nanogrow-gano-la-edicion-local-startup-world-cup-y-viajara-san-francisco-competir-us-1-millon-n6056471
[nanogrowbiotech.com] Nanogrow | Transforming Health with Innovative Antibody Solutions | https://nanogrowbiotech.com/
[Perplexity Sonar Pro Brief, retrieved 2024] Nanogrow Biotech Brief | [URL not provided in structured facts]
[AMEDNA] Lucía Vanrell recognized as "Emprendedora Navarra 2025" | [URL not provided in structured facts]
[Cadena SER Navarra] Innovation Award from Cadena SER Navarra | [URL not provided in structured facts]
[Sanofi, 2018] Sanofi completes acquisition of Ablynx | [URL not provided in structured facts]
[FiercePharma, 2018] Sanofi to buy Ablynx for €3.9B | [URL not provided in structured facts]
[Evaluate Pharma, 2024] World Preview 2024, Outlook to 2030 | [URL not provided in structured facts]
[Grand View Research, 2024] Antibody Drug Conjugates Market Size Report, 2024-2030 | [URL not provided in structured facts]
[Merck] Merck & Co. Corporate Website | [URL not provided in structured facts]
[Novartis] Novartis Corporate Website | [URL not provided in structured facts]
[Boehringer Ingelheim] Boehringer Ingelheim Corporate Website | [URL not provided in structured facts]
Articles about Nanogrow
- Nanogrow's Camelid Nanobodies Aim for a Cream Instead of an IV Bag — The Pamplona biotech startup, with a $1.2M seed round, is betting its localized delivery can carve a niche against giants like Sanofi.